We are live on ! Find out more
ACRS icon

Aclaris Therapeutics
ACRS

127 hedge funds and large institutions have $957M invested in Aclaris Therapeutics in 2022 Q3 according to their latest regulatory filings, with 19 funds opening new positions, 48 increasing their positions, 26 reducing their positions, and 6 closing their positions.

New
Increased
Maintained
Reduced
Closed

217% more first-time investments, than exits

New positions opened: 19 | Existing positions closed: 6

85% more repeat investments, than reductions

Existing positions increased: 48 | Existing positions reduced: 26

12% more capital invested

Capital invested by funds: $851M → $957M (+$106M)

10% more funds holding

Funds holding: 115 → 127 (+12)

1% more call options, than puts

Call options by funds: $362K | Put options by funds: $357K

0.32% more ownership

Funds ownership: 95.03% → 95.35% (+0.32%)

0% more funds holding in top 10

Funds holding in top 10: 9 → 9 (0)

Holders
127
Holders Change
+12
Holders Change %
+10.43%
% of All Funds
2.19%
Holding in Top 10
9
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.16%
New
19
Increased
48
Reduced
26
Closed
6
Calls
$362K
Puts
$357K
Net Calls
+$5K
Net Calls Change
-$250K

Top Buyers

1
O
OrbiMed
New York
+$6.82M
2
Walleye Capital
Walleye Capital
New York
+$4.25M
3
Charles Schwab
Charles Schwab
California
+$3.91M
4
Citadel Advisors
Citadel Advisors
Florida
+$2.6M
5
BlackRock
BlackRock
New York
+$2.21M

Top Sellers

1
Wellington Management Group
Wellington Management Group
Massachusetts
-$22.8M
2
Renaissance Technologies
Renaissance Technologies
New York
-$2.28M
3
LCM
Laurion Capital Management
New York
-$2.13M
4
Assenagon Asset Management
Assenagon Asset Management
Luxembourg
-$1.55M
5
Fidelity Investments
Fidelity Investments
Massachusetts
-$1.53M
Name Holding Trade Value Shares
Change 		Change in
Stake
ACM
26
Aisling Capital Management
New York
$9.99M – – –
Northern Trust
27
Northern Trust
Illinois
$8.71M +$470K +29,805 +6%
SCM
28
Silverarc Capital Management
Massachusetts
$8.56M +$66.7K +4,231 +0.8%
JP Morgan Chase
29
JP Morgan Chase
New York
$7.13M -$136K -8,631 -2%
Goldman Sachs
30
Goldman Sachs
New York
$6.65M +$226K +14,358 +4%
FLSM
31
Frazier Life Sciences Management
California
$6.43M – – –
Charles Schwab
32
Charles Schwab
California
$6.34M +$3.91M +248,235 +161%
SSA
33
Schonfeld Strategic Advisors
New York
$6.3M -$569K -36,100 -8%
Verition Fund Management
34
Verition Fund Management
Connecticut
$5.86M +$596K +37,841 +11%
PA
35
Perceptive Advisors
New York
$5.37M – – –
IHAM
36
Integral Health Asset Management
New York
$5.35M +$851K +54,029 +19%
Walleye Capital
37
Walleye Capital
New York
$4.25M +$4.25M +269,948 New
Bank of New York Mellon
38
Bank of New York Mellon
New York
$3.68M +$499K +31,683 +16%
PHP
39
Parkman Healthcare Partners
Connecticut
$3.68M -$1.12M -71,217 -23%
N
40
Nuveen
North Carolina
$3.48M -$461K -29,290 -12%
HS
41
HighVista Strategies
Massachusetts
$3.43M +$4.57K +290 +0.1%
Millennium Management
42
Millennium Management
New York
$3.21M +$80.5K +5,111 +3%
Assenagon Asset Management
43
Assenagon Asset Management
Luxembourg
$3.07M -$1.55M -98,122 -33%
Morgan Stanley
44
Morgan Stanley
New York
$2.64M +$106K +6,702 +4%
ACP
45
Acuta Capital Partners
California
$2.53M -$504K -32,000 -17%
AAA
46
Affinity Asset Advisors
New York
$2.15M +$574K +36,434 +36%
UOC
47
UBS O'Connor
Illinois
$1.78M – – –
Swiss National Bank
48
Swiss National Bank
Switzerland
$1.74M +$150K +9,500 +9%
VOYA Investment Management
49
VOYA Investment Management
Georgia
$1.68M +$1.33M +84,287 +375%
Balyasny Asset Management
50
Balyasny Asset Management
Illinois
$1.67M +$1.67M +106,147 New
1
2
3 4 5

ACRS Hedge Fund Activity: Q3 2022 in Review

127 of the 5,805 institutional investors tracked by Wall St. Rank reported a position in Aclaris Therapeutics (ACRS) for Q3 2022, worth a combined $957M — up 12% from $851M a quarter earlier.

Buyers outnumbered sellers: 19 funds opened new ACRS positions and 6 closed out — a net gain of 13 holders — while 48 added to existing stakes and 26 trimmed.

The largest buyer was OrbiMed, adding an estimated $6.82M. The largest seller was Wellington Management Group, cutting an estimated $22.8M.

  • 127 institutional investors held Aclaris Therapeutics (ACRS) as of Q3 2022, up from 115 in Q2 2022.
  • Funds reported $957M of Aclaris Therapeutics stock for Q3 2022, up 12% quarter-over-quarter.
  • 19 funds opened new Aclaris Therapeutics positions in Q3 2022 and 6 closed out, a net change of +13 holders.
  • The largest Aclaris Therapeutics buyer in Q3 2022 was OrbiMed, an estimated $6.82M added.
  • The largest Aclaris Therapeutics seller in Q3 2022 was Wellington Management Group, an estimated $22.8M sold.

Based on aggregated 13F filings for Q3 2022.